European Pharmaceutical Review

JUNE 28, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a first-of-its-kind trial to run this year to test psychedelic drugs as a treatment for major depressive disorder (MDD). The clinical trial will combine dosages of a new psilocin-based drug with specialist therapy.

Ethics 74

Ethics Medicine Pharma FDA 74

Pharmacy Times

MARCH 11, 2024

If clinical trials continue to show that psychedelics offer safe and long-lasting results, then psychedelic-assisted therapy could flourish as a treatment in the mental health space.

52

52

Pharmacy Times

MARCH 27, 2024

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

Medicine 59

Medicine 59

European Pharmaceutical Review

DECEMBER 13, 2022

North American psychedelic drug developers Mindset, PharmAla, Mydecine and Psyence have signed with clinical research organisation (CRO) Clerkenwell Health to trial therapies for mental health conditions, in London, UK, to benefit from the country’s swift drug regulatory process.

Medicine 99

Medicine Food and Drug Administration Ethics Government 99

PM360

MARCH 24, 2023

In place of NFTs, psychedelics were given their own conference track this year. Psychedelics It was hard not to notice the amount of programming related to psychedelics. Even the SXSW tote bags and signage in the convention center had a psychedelic theme. But a lot was shared at this year’s SXSW that had staying power.

Media 119

Media Engineering Healthcare Healthcare 119

MedCity News

NOVEMBER 4, 2022

Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.

Management 95

Management Biopharma Pharma 95

Pharmacy Times

OCTOBER 18, 2023

In the clinical setting, psychedelic medicine has promise as a safe and efficacious treatment for PTSD, TBIs, and other mental health issues.

Medicine 59

Medicine 59

Pharmacy Times

JANUARY 13, 2023

Jordan Sloshower, MD, MSc, explains his experience working in several clinical trials investigating psilocybin-assisted therapy.

Medicine 55

Medicine 55

Pharmacy Times

MAY 19, 2023

Rick Strassman, MD, a clinical researcher, author, and expert in psychedelic medicines, sat down to discuss pharmacists' role in adverse event management.

Medicine 49

Medicine Management 49

European Pharmaceutical Review

DECEMBER 21, 2022

There is growing interest in the use of psychedelic-assisted therapy for treatment of mental health conditions. Here, Guy Goodwin, Chief Medical Officer of COMPASS Pathways, explores the potential of tryptamines to treat depression, sharing results from a recent clinical trial. mRNA therapeutics: a limitless revolution in medicine.

Medicine 77

Medicine Medical Pharmaceutical 77

European Pharmaceutical Review

NOVEMBER 4, 2022

Participants stayed in specialised rooms designed to provide a non-clinical, calming atmosphere. The therapy’s psychedelic effects lasted between six and eight hours. Further clinical trial results. The investigation interviewed patients on day two, and weeks one, three, six, nine, and 12 of the trial.

Patients 93

Patients Medicine Medical Pharmaceutical 93

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Consequently, the US Food and Drug Administration (FDA) and other agencies are keen to see “accelerated development” programmes in areas where there is a significant unmet clinical need. These drugs can be approved based on a surrogate endpoint, but the applicant provides an undertaking to subsequently perform confirmatory clinical studies.

Food and Drug Administration 76

Food and Drug Administration FDA Safety Food 76

European Pharmaceutical Review

DECEMBER 18, 2023

Findings from a small Phase II clinical trial indicate that psilocybin, a hallucinogenic chemical found in certain mushrooms of the genus Psiloybe , may benefit individuals with cancer and major depression. Psychedelic medicines: are they gaining traction in Europe?

Food and Drug Administration 109

Food and Drug Administration Patients Side effects Safety 109

pharmaphorum

NOVEMBER 3, 2022

The psychedelic compound in magic mushrooms – psilocybin – can improve the symptoms of severe depression, according to the largest randomised, controlled trial of the therapy carried out to date. The study tested two doses of the psychedelic drug – 10mg and 25 mg – with a 1 mg dose used as a control group.

Side effects 95

Side effects Medicine Patients Leads 95

European Pharmaceutical Review

JANUARY 25, 2023

DMT could offer a better clinical alternative to other psychedelics, such as psilocybin and LSD, which require lengthy treatment sessions. Patients were dosed with a short IV infusion of 21.5mg of SPL026, resulting in a 20 to 30-minute psychedelic experience.

Safety 133

Safety Patients Pharma Medical 133

pharmaphorum

OCTOBER 24, 2022

Psychedelic medicines company Beckley Psytech has reached an agreement to acquire its rival Eleusis Therapeutics, in alignment with predictions that the sector is heading for a period of consolidation. Beckley’s takeover of Eleusis brings together two UK players in the psychedelics category with complementary pipelines.

Medicine 44

Medicine Leads Patients 44

European Pharmaceutical Review

DECEMBER 18, 2023

Dr Maher elaborated on data from a clinical trial of GD2-specific CAR T-cells in children with relapsed refractory neuroblastoma. The researchers stated that DMT could provide a superior alternative to other psychedelics, such as psilocybin and LSD, which require lengthy treatment sessions.

Manufacturing 96

Manufacturing Food and Drug Administration Medicine Pharmaceutical manufacturing 96

European Pharmaceutical Review

SEPTEMBER 27, 2023

While the efficacy observed in the non-SSRI cohort was comparable to the efficacy data previously observed in Small Pharma’s SPL026 Phase IIa clinical trial. A marked improvement was observed between the antidepressant effect of SPL026 treatment in the SSRI cohort compared to the non-SSRI cohort.

Pharma 101

Pharma Biopharma Patients Leads 101

European Pharmaceutical Review

DECEMBER 15, 2022

These new connections appear to remain even when psilocybin’s psychedelic effect has worn off. Clinical trials are underway to study psilocybin therapy for treatment-resistant depression. Ongoing clinical development has highlighted the practical challenges associated with psilocybin therapy that will need to be overcome.

Food and Drug Administration 69

Food and Drug Administration Healthcare Healthcare Food 69